Acute Spinal Cord Injury - Pipeline Review, H2 2015

Date: August 26, 2015
Pages: 52
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A89420E22A1EN
Leaflet:

Download PDF Leaflet

Acute Spinal Cord Injury - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Spinal Cord Injury - Pipeline Review, H2 2015’, provides an overview of the Acute Spinal Cord Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Acute Spinal Cord Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Spinal Cord Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Spinal Cord Injury Overview
Therapeutics Development
Pipeline Products for Acute Spinal Cord Injury - Overview
Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis
Acute Spinal Cord Injury - Therapeutics under Development by Companies
Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes
Acute Spinal Cord Injury - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acute Spinal Cord Injury - Products under Development by Companies
Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes
Acute Spinal Cord Injury - Companies Involved in Therapeutics Development
Kringle Pharma, Inc.
Neuralstem, Inc.
Neuronax SAS
Vertex Pharmaceuticals Incorporated
Acute Spinal Cord Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cell Therapy for Spinal Cord Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSI-566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VX-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Spinal Cord Injury - Recent Pipeline Updates
Acute Spinal Cord Injury - Dormant Projects
Acute Spinal Cord Injury - Discontinued Products
Acute Spinal Cord Injury - Product Development Milestones
Featured News & Press Releases
Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries
Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Spinal Cord Injury, H2 2015
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015
Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015
Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015
Acute Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015
Acute Spinal Cord Injury - Dormant Projects, H2 2015
Acute Spinal Cord Injury - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Acute Spinal Cord Injury, H2 2015
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Companies Mentioned

Kringle Pharma, Inc.
Neuralstem, Inc.
Neuronax SAS
Vertex Pharmaceuticals Incorporated
Skip to top


Ask Your Question

Acute Spinal Cord Injury - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: